Physician

Robert Brian Berryman, M.D.

According to 2025 Medicare claims, Robert Berryman, M.D. (NPI: 1871535823) practices medical oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Dallas, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1003083445; TIN: 752131429) and primary practice location at 75246-2012.

Berryman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 291 traditional Medicare patients, billed 186,361 HCPCS/CPT codes, and received $4,355,314 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,173 prescription claims across 276 beneficiaries totaling $6,715,660 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 55 claims. Open Payments data shows 86 records totaling $47,817. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,206,670 to $4,355,314. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,152,834 to $6,715,660. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,448 and ending at $1,416.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	273	297,433	$2,206,670
2016	294	288,634	$4,043,494
2017	300	360,089	$4,194,302
2018	285	307,552	$3,948,360
2019	295	308,057	$3,571,734
2020	272	270,037	$4,365,078
2021	272	272,770	$4,567,194
2022	270	246,560	$4,870,536
2023	254	195,409	$4,172,186
2024	291	186,361	$4,355,314

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	192	3,941	$2,152,834
2016	235	4,643	$2,923,141
2017	247	4,731	$3,592,077
2018	240	4,555	$5,275,302
2019	252	4,461	$5,800,868
2020	252	5,084	$7,772,045
2021	252	4,642	$8,399,291
2022	273	4,690	$8,930,202
2023	278	4,335	$6,877,367
2024	276	4,173	$6,715,660

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	18	141	$12,248
2016	13	132	$10,140
2017	N/R	141	$8,581
2018	N/R	134	$9,243
2019	N/R	139	$48,223
2020	N/R	119	$48,634
2021	N/R	125	$6,215
2022	N/R	193	$8,259
2023	N/R	146	$6,135
2024	N/R	55	$1,418

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	199	917	$92
80053	Blood test, comprehensive group of blood chemicals	207	1,567	$10
36415	Insertion of needle into vein for collection of blood sample	210	1,585	$9
83735	Magnesium level	207	1,516	$7
83615	Lactate dehydrogenase (enzyme) level	207	1,521	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	74	2,216	$1,263,119
Pomalyst	Pomalidomide	45	1,260	$999,962
Venclexta	Venetoclax	49	1,424	$526,488
Xpovio	Selinexor	18	504	$524,494
Revlimid	Lenalidomide	21	588	$419,418

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	15	$946
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	24	$395
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	16	$77

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	79	$17,637	Karyopharm Therapeutics Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	7	$30,181	Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert Brian Berryman, M.D.?

Tedicare shows public-source Medicare data for Robert Brian Berryman, M.D. (NPI 1871535823), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert Brian Berryman, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Robert Brian Berryman, M.D.?

Robert Brian Berryman, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1003083445) in the available physician profile data.

Does Robert Brian Berryman, M.D. have Open Payments data?

Robert Brian Berryman, M.D. has 86 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.